The amplification of DNTTIP2 is associated with poor prognosis in glioma patients, and its hypermethylation is also linked to unfavorable outcomes, highlighting its potential as a biomarker and therapeutic target [52]. Here, DNTTIP2 is linked to central nervous system cancer.